Expression of HDAC1 and CBP/p300 in human colorectal carcinomas

Journal of Clinical Pathology

Volumn 60, Issue 11, 2007, Pages 1205-1210

  Ishihama, Katsuyoshi ^a   Yamakawa, Mitsunori ^a   Semba, Shuho ^a   Takeda, Hiroaki ^a   Kawata, Sumio ^a   Kimura, Seishi ^a   Kimura, Wataru ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE 1; PROTEIN P300;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; AGED; COLORECTAL NEOPLASMS; CREB-BINDING PROTEIN; E1A-ASSOCIATED P300 PROTEIN; FEMALE; GENE EXPRESSION; HISTONE DEACETYLASES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 36049045474     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.029165     Document Type: Article

References (41)

1. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000;403:41-5.
2. Fischle W, Dequiedt F, Hendzel MJ, et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell 2002;9:45-57.
3. Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3. Science 1996;272:408-11.
4. Maeda T, Towatari M, Kosugi H, et al. Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 2000;96:3847-56.
5. Richon VM, Sandhoff TW, Rifkind RA, et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000;97:10014-19.
6. Vigushin DM, Ali S, Pace PE, et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 2001;61:971-6.
7. Butler LM, Agus DB, Scher HI, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000;60:5165-70.
8. Yarden RI, Brody LC. BRCA1 interacts with components of the histone deacetylase complex. Proc Natl Acad Sci USA 1999;96:4983- 8.
9. Kim MS, Kwon HJ, Lee YM, et al. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 2001;7:437-43.
10. Suzuki T, Yokozaki H, Kuniyasu H, et al. Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines. Int J Cancer 2000;88:992-7.
11. Shikama N, Lee CW, France S, et al. A novel cofactor for p300 that regulates the p53 response. Mol Cell 1999;4:365-76.
12. Arany Z, Sellers WR, Livingston DM, et al. E1A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators. Cell 1994;77:799-800.
13. Ait-Si-Ali S, Ramirez S, Barre FX, et al. Histone acetyltransferase activity of CBP is controlled by cycle-dependent kinases and oncoprotein E1A. Nature 1998;396:184-6.
14. Chakravarti D, Ogryzko V, Kao HY, et al. A viral mechanism for inhibition of p300 and PCAF acetyltransferase activity. Cell 1999;96:393-403.
15. Kawasaki H, Eckner R, Yao TP, et al. Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation. Nature 1998;393:284-9.
16. Murata T, Kurokawa R, Krones A, et al. Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi disease. Hum Mol Genet 2001;91:1154-60.
17. Petrij F, Giles RH, Dauwerse HG, et al. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 1995;376:348-51.
18. Sakai K, Nagahara H, Abe K, et al. Loss of heterozygosity on chromosome 16 in hepatocellular carcinoma. J Gastroenterol Hepatol 1992;7:288-92.
19. Muraoka M, Konishi M, Kikuchi-Yanoshita R, et al. p300 gene alterations in colorectal and gastric carcinomas. Oncogene 1996;12:1565-9.
20. Borrow J, Stanton VP Jr, Andresen JM, et al. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 1996;14:33-41.
21. Giles RH, Peters DJ, Breuning MH. Conjunction dysfunction: CBP/p300 in human disease. Trends Genet 1998;14:178-83.
22. Japanese Society for Cancer of the Colon and Rectum. General rules for clinical and pathological studies on cancer of colon, rectum and anus. 6th edn. Tokyo: Kanehara, 1998.
23. Sobin LH, Wittekind C. TNM classification of malignant tumors. 5th edn. New York: Wiley-Liss, 1997.
24. Handa K, Yamakawa M, Takeda H, et al. Expression of cell cycle markers in colorectal carcinoma: superiority of cyclin A as an indicator of poor prognosis. Int J Cancer 1999;84:225-33.
25. King RJ, Coffer AI, Gilbert J, et al. Histochemical studies with a monoclonal antibody raised against a partially purified soluble estradiol receptor preparation from human myometrium. Cancer Res 1985;45:5728-33.
26. Tsuge K, Takeda H, Kawada S, et al. Characterization of dendritic cells in differentiated thyroid cancer. J Pathol 2005;205:565-76.
27. Choi JH, Kwon HJ, Yoon BI, et al. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 2001;92:1300-4.
28. Di Padova M, Bruno T, De Nicola F, et al. Che-1 arrests human colon carcinoma cell proliferation by displacing HDAC1 from the p21WAF1/CIP1 promoter. J Biol Chem 2003;278:36496-504.
29. Ionov Y, Matsui S, Cowell JK. A role for p300/CREB binding protein genes in promoting cancer progression in colon cancer cell lines with microsatellite instability. Proc Natl Acad Sci USA 2004;101:1273- 8.
30. Murphy M, Ahn J, Walker KK, et al. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev 1999;13:2490-501.
31. Hayashi R, Wada H, Ito K, et al. Effects of glucocorticoids on gene transcription. Eur J Pharmacol 2004;500:51-62.
32. McIntyre A, Gibson PR, Young GP. Butyrate production from dietary fibre and protection against large bowel cancer in a rat model. Gut 1993;34:386-91.
33. Archer S, Meng S, Wu J, et al. Butyrate inhibits colon carcinoma cell growth through two distinct pathways. Surgery 1998;124:248-53.
34. Barnard JA, Warwick G. Butyrate rapidly induces growth inhibition and differentiation in HT-29 cells. Cell Growth Differ 1993;4:495-501.
35. Marks PA, Richon VM, Breslow R, et al. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 2001;13:477-83.
36. Lau OD, Kundu TK, Soccio RE, et al. HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol Cell 2000;5:589-95.
37. Kalkhoven E. CBP and p300: HATs for different occasions. Biochem Pharmacol 2004;68:1145-55.
38. Iyer NG, Özdag H, Caldas C. p300/CBP and cancer. Oncogene 2004;23:4225-31.
39. Ma H, Nguyen C, Lee KS, et al. Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene 2005;24:3619-31.
40. Cong SY, Pepers BA, Evert BO, et al. Mutant huntingtin represses CBP, but not p300, by binding and protein degradation. Mol Cell Neurosci 2005;30:12-23.
41. Kim JH, Cho EJ, Kim ST, et al. CtBP represses p300-mediated transcriptional activation by direct association with its bromodomain. Nat Struct Mol Biol 2005;12:423-8.